Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer

BE Kiely; ML Friedlander; RL Milne; L Stanhope; P Russell; MA Jenkins; P Weideman; SA McLachlan; P Grant; JL Hopper; KA Phillips

Journal article

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer

BE Kiely, ML Friedlander, RL Milne, L Stanhope, P Russell, MA Jenkins, P Weideman, SA McLachlan, P Grant, JL Hopper, KA Phillips

Familial Cancer | SPRINGER | Published : 2011

DOI: 10.1007/s10689-011-9435-0

Download PDF

Abstract

The aim of this study was to describe the type of risk-reducing gynaecologic surgery (RRGS) and the extent of pathological evaluation being undertaken for Australasian women at high familial risk of pelvic serous cancer. Surgical and pathology reports were reviewed for women with BRCA1/BRCA2 mutations, or a family history of breast and ovarian cancer, who underwent RRGS between 1998 and 2008. "Adequate" surgery was defined as complete removal of all ovarian and extra-uterine fallopian tube tissue. "Adequate" pathology was defined as paraffin embedding of all removed ovarian and tubal tissue. Predictors of adequacy were assessed using logistic regression. There were 201 women, including 173 m..

View full abstract

University of Melbourne Researchers

Roger Milne Author

Mark Jenkins Author

Sue-Anne McLachlan Author

Kelly Phillips Author

Related Projects (2)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

Grants

Awarded by Seventh Framework Programme

Funding Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC) of Australia (#145684, 288704, 454508) and by the National Breast Cancer Foundation and Cancer Australia (#628333). KA Phillips is the Cancer Council Victoria Dr John Colebatch Clinical Research Fellow. JL Hopper is an Australia Fellow of the NHMRC and Victorian Breast Cancer Research Consortium Group Leader. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council of Australia and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, the Cancer Foundation of Western Australia. We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, and the heads and staff of the Family Cancer Clinics for their contributions to this resource, and the many families who contribute to kConFab.